Background: Bipolar Disorder (BD) is a psychiatric disorder characterized by mood disturbances.
The pathophysiology of BD is still poorly understood. In the last years, research studies focused
on the role of inflammation in BD.
Objective: Performed a systematic review and meta-analysis to evaluate the potential effect of the cyclo-
oxygenases (Cox)-2 inhibitor Celecoxib adjunct treatment in BD through randomized controlled
Method: A search on the electronic databases was proceeded, on MEDLINE, EMBASE, Scopus,
Cochrane Central Register of Controlled Trials (CENTRAL), Biomed Central, Web of Science,
IBECS, LILACS, PsycINFO, Congress Abstracts, and Grey literature (Google Scholar and the British
Library) for studies published from January 1990 to February 2018. A search strategy was developed
using the terms: “Bipolar disorder” or “Bipolar mania” or “Bipolar depression” or “Bipolar mixed” or
“Bipolar euthymic” and “Celecoxib” or “Cyclooxygenase-2 inhibitors” or “Cox-2 inhibitors” as text
words and Medical Subject Headings (i.e., MeSH and EMTREE) and searched. The therapeutic effects
of adjunctive treatment with Celecoxib were analyzed. The meta-analysis was performed including the
results of the Young Mania Rating Scale (YMRS) at the end of RCT.
Results: Three primary studies were included in the systematic review, with a total of 121 patients.
The meta-analysis showed a significant effect on the YMRS scores from patients with BD who used
Celecoxib adjuvant treatment in comparison to placebo.
Conclusion: The systematic review suggests that adjuvant treatment with Celecoxib improves the response
of major treatments in patients with BD when compared with adjuvant placebo treatment.